立体定向放疗加厄洛替尼与厄洛替尼单药治疗IV期非小细胞肺癌的临床效果比较  

Comparison of outcomes in patients with stage IV non-small cell lung cancer treated with a combination of stereotactic body radiation therapy and erlotinib

作　　者：邱卉[1] 申戈[1] 李丹[1] 董大鹏[1] 郝瑞敏[1] 周明[1] 杨刚[1] 周仕香[1] 孙慧茹[1] 卜丽娜[1] 吴世凯[1] 

机构地区：[1]军事医学科学院附属医院放疗中心,北京100071

出　　处：《慢性病学杂志》2015年第4期367-370,共4页Chronic Pathematology Journal

基　　金：吴阶平基金资助项目(320.6750.12332)

摘　　要：目的比较IV期非小细胞肺癌(non small cell lung cancer,NSCLC)患者接受立体定向放疗(Stereotactic Body Radiation Therapy,SBRT)加厄洛替尼和厄洛替尼单药的临床结果。方法具有可测量病灶的IV期NSCLC,分别接受SBRT序贯厄洛替尼(150 mg,口服,1次/d)或厄洛替尼单药,至疾病进展或出现不能耐受的不良反应。观察无进展生存时间(PFS),总生存时间(OS)、肿瘤缓解率(ORR)、疾病控制率(DCR)和不良反应。结果本研究入组时间2011年6月22日至2014年9月30日,共入组42例,两组各21例。中位随访时间联合组24.4个月(4.3~35.0个月),单药组24.3个月(8.5~39.2个月)。中位PFS联合组8个月(95%CI 4.0~14.0个月),单药组5个月(95%CI 3.0~9.0个月),P=0.3703。OS联合组23.7个月(95%CI 15.4~33.8个月),单药组20.1个月(95%CI 16.2~NR),P=0.5829)。两组不良反应发生率和严重程度差异无统计学意义。结论 SBRT序贯厄洛替尼治疗NSCLC时PFS及OS略好于单药组,但无统计学差异。Objective To compare the outcomes in patients with non-small cell lung cancer(NSCLC)treated with a combination of stereotactic body radiation therapy(SBRT) and erlotinib versus erlotinib alone. Methods Patients with stage IV NSCLC were treated with a combination of SBRT and erlotinib versus erlotinib alone until time to progress or untolerated adverse effect. Erlotinib was orally administrated 150 mg qd. The clinical observation indices include progression free survival(PFS), overall survival(OS), overall response rate(ORR), disease control rate(DCR) and adverse effect. Results The study period is from 22 June 2011 to September 30, 2014. There were a total of 42 patients enrolled,including 21 patients in each group. The median PFS was 8 months(95% confidence interval(CI) 4.0-14.0 months) in the combination group and 5 months(95% CI 3.0-9.0) in the erlotinib alone group,with P value 0.3703. The median OS was 23.7 months(95% CI 15.4.0-33.8 months) in the combination group and 20.1 months(95% CI 16.2-NR) in the erlotinib alone group, with P value0.5829. The median follow-up duration was 6.5 months(95% CI 3-18 months) for the survivors. There was no difference fro the adverse effect between two groups. Conclusions The PFS and OS of NSCLC patients treated with a combination of SBRT and erlotinib were slightly prolonged, compared to those treated with erlotinib alone. However, there is no statistically significant difference in PFS and OS between the two groups.

关 键 词：IV期 非小细胞肺癌 厄洛替尼 立体定向放疗 

分 类 号：R734.2[医药卫生—肿瘤]